CE Mark Approval Granted to MatOrtho’s Hip Resurfacing Tech

MatOrtho has earned CE Mark approval for its ReCerf Hip Resurfacing Arthroplasty (HRA), expanding access to the technology across the United Kingdom, Europe, and internationally where CE marking supports market access.

“This is more than a regulatory milestone. It represents two decades of focused effort to improve hip resurfacing through an advanced material,” MatOrtho Founder Mike Tuke stated. “That became a possibility with BIOLOX delta and cooperation with CeramTec A.G. which led in stages to ReCerf—an all-ceramic resurfacing implant that is already delivering excellent results. We’re proud to make this more widely available to specialist hip resurfacing surgeons, and patients who want to stay active.”

ReCerf is touted as the world’s first commercially available ceramic HRA, first approved by Australia’s Therapeutic Goods Administration in November 2024. Since its initial use in 2018, more than 1,600 patients have received the device. Patient-reported outcomes are highly positive, and the revision rate remains very low up to six years.

Made from BIOLOX delta ceramic, ReCerf eliminates concerns historically associated with metal-on-metal bearings and preserves more of the patient’s natural bone. For surgeons, it offers a familiar procedure underpinned by improved materials, and is supported by a company long recognized as the home of modern hip resurfacing, according to the company.

ReCerf’s availability under CE marking is matched by a strong commitment to responsible adoption. MatOrtho supports structured education, careful patient selection, and ongoing clinical monitoring. A peer-led surgeon training programme is already in place to ensure safe and effective use.

MatOrtho (formerly Finsbury Orthopaedics) develops joint replacement technologies that improve patient outcomes and set new clinical standards. The company is based in the United Kingdom.